Skip to main content
OpenTrials
Completed

NCT Number: NCT02103842

Omega-3 Fatty Acids to Combat Sarcopenia

The purpose of this study is to determine how omega-3 fatty acids influence muscle protein metabolism and mitochondrial physiology in the context of human aging.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcopenia Atrophy Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-35 or 65-85 years

Exclusion criteria

  • Current use of omega-3 nutritional supplements
  • Fasting plasma glucose ≥126 mg/dL
  • Active coronary artery disease
  • Participation in structured exercise (>3 times per week for 30 minutes or longer)
  • Smoking
  • Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)
  • Renal failure (serum creatinine > 1.5mg/dl)
  • Chronic active liver disease (Bilirubin > 17mmol/L, AST>144IU/L, or ALT>165IU/L)
  • Anti-coagulant therapy (warfarin/heparin)
  • INR >3
  • Use of systemic glucocorticoids
  • Chronic use of NSAIDS or aspirin
  • Pregnancy or breastfeeding
  • Alcohol consumption greater than 2 glasses/day
  • Hypothyroidism
  • Fish or shellfish allergy

Treatment and study plan

Omega-3 Fatty acids

Drug

Primary outcomes

  1. Change in Muscle protein synthesis

    Time frame: Baseline and following 4 months intervention

    Skeletal muscle protein synthesis will be measured from the rate of incorporation of infused amino acids measured by mass spectrometry.

  2. Change in Muscle mitochondrial function

    Time frame: Baseline and following 4 months intervention

    Mitochondrial function will be measured in isolated mitochondria by high-resolution respirometry.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Apr 4, 2014
Registry last updated
Dec 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.